Fresenius agrees two acquisitions to expand Kabi drugs unit

The German healthcare group says the acquisitions will accelerate strategic growth in biopharmaceuticals and MedTech 

Fresenius Kabi will acquire Ivenix for $240 million upfront, plus milestone payments contingent on commercial and operating targets, and mAbxience for $553 million plus milestone payments.  

Fresenius Kabi says the acquisitions are part of a wider growth strategy where the company’s presence is enhanced in the biopharmaceuticals and MedTech markets. The company also hopes Ivenix will transform its product offering.  

Ivenix, a US-based company, received US Food and Drug Administration approval for its infusion system and accompanying software in 2019, which Kabi will combine with its offering of intravenous fluids and infusion devices.  

Commenting on the Ivenix acquisition, Fresenius Kabi CEO Michael Sen it would “complement and strengthen our existing infusion therapy offering” and allow the company to “create a superior portfolio for the US market”.  

Sen added that buying a majority stake in mAbxience is expected to be a “highly complementary transaction in terms of biologics pipeline, manufacturing capabilities and the business model”.  

“mAbxience and Ivenix as portfolio advancements are good for patients, good for healthcare providers and our company,” he said.  

The transactions are subject to regulatory approval and other customary closing conditions and are expected to close by mid-2022.